Phencyclidine (PCP)-Related Psychiatric Disorders: Multimedia

References

1. Enomoto T, Noda Y, Mouri A, Shin EJ, Wang D, Murai R. Long-lasting impairment of associative learning is correlated with a dysfunction of N-methyl-D-aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine. Mol Pharmacol. Dec 2005;68(6):1765-74. [Medline].

2. Hajszan T, Leranth C, Roth RH. Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex. Biol Psychiatry. Sep 15 2006;60(6):639-44. [Medline].

3. Kehrer C, Maziashvili N, Dugladze T, Gloveli T. Altered Excitatory-Inhibitory Balance in the NMDA-Hypofunction Model of Schizophrenia. Front Mol Neurosci. 2008;1:6. [Medline].

4. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future, National Results on Adolescent Drug Use. Overview of Key Findings. Monitoring the Future. Available at http://www.monitoringthefuture.org/pubs/monographs/overview2008.pdf. Accessed April 9, 2009.

5. Wong LK, Biemann K. Metabolites of phencyclidine. Clin Toxicol. 1976;9(4):583-91. [Medline].

6. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. June 1989;244:1360-1362. [Medline].

7. Corales RL, Maull KI, Becker DP. Phencyclidine abuse mimicking head injury. JAMA. Jun 13 1980;243(22):2323-4. [Medline].

8. Serra A, Leigh RJ. Diagnostic value of nystagmus: spontaneous and induced ocular oscillations. J Neurol Neurosurg Psychiatry. Dec 2002;73(6):615-8. [Medline]. [Full Text].

9. Barton CH, Sterling ML, Vaziri ND. Rhabdomyolysis and acute renal failure associated with phencyclidine intoxication. Arch Intern Med. 1980;140:568-569. [Medline]. [Full Text].

10. Prochaska JO and DiClemente CC. Transtheoretical therapy: Toward a more integrative model of change. Psychotherapy: Theory, Research and Practice. 1982;19:276-288.

11. Tennant FS Jr, Rawson RA, McCann M. Withdrawal from chronic phencyclidine (PCP) dependence with desipramine. Am J Psychiatry. Jun 1981;138(6):845-7. [Medline].

12. Pestaner JP, Southall PE. Sudden death during arrest and phencyclidine intoxication. Am J Forensic Med Pathol. Jun 2003;24(2):119-22. [Medline].

13. Aniline O, Allen RE, Pitts FN Jr. The urban epidemic of phencyclidine use: laboratory evidence from a public psychiatric hospital inpatient service. Biol Psychiatry. Oct 1980;15(5):813-7. [Medline].

14. Camilleri JG. The use of phencyclidine (Cl-395) in obstetric procedures: a preliminary communication. Anesthesia. 2007;17(4):422-426. [Full Text].

15. Crider R. Phencyclidine: changing abuse patterns. NIDA Res Monogr. 1986;64:163-73. [Medline].

16. Davis BL. The PCP epidemic: a critical review. Int J Addict. Oct 1982;17(7):1137-55. [Medline].

17. Gorelick DA, Balster RL. Phencyclidine (PCP). In: Kupfer DJ, Bloom FE. Psychopharmacology - the fourth generation of progress. 4. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:[Full Text].

18. Jodo E, Suzuki Y, Katayama KY, Takeuchi S, Niwa SI, Kayama Y. Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampal-prefrontal pathway. Cerebral Cortex. 2005;15(5):663-669.

19. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Various stimulant drugs show continuing declines among teens in 2008, most illicit drugs hold steady. University of Michigan News Service, Ann Arbor, MI. Available at http://www.monitoringthefuture.org. Accessed 02/04/2009.

20. Koek W, Woods JH. Correlations between phencyclidine-like activity and N-methyl-D-aspartate antagonism: behavioral evidence. In: Sigma and Phencyclidine-like Compounds as Molecular Probes in Biology. Ann Arbor, Mich: NPP Books; 1988.

21. Lehrmann E, Colantuoni C, Deep-Soboslay A, Becker KG, Lowe R, Huestis MA, et al. Transcriptional changes common to human cocaine, cannabis, and phencyclidine abuse. PLoS ONE [serial online]. 1(1):e114. Available at http://www.plosone.org/article/fecthArticle.action?articleURI=info:do.

22. Lundberg GD, Gupta RC, Montgomery SH. Phencyclidine: patterns seen in street drug analysis. Clin Toxicol. 1976;9(4):503-11. [Medline].

23. McCarron MM, Schulze BW, Thompson GA. Acute phencyclidine intoxication: clinical patterns, complications, and treatment. Ann Emerg Med. Jun 1981;10(6):290-7. [Medline].

24. Meyer JS, Greifsenstein F, Devault M. A new drug causing symptoms of sensory deprivation. J Nerv Ment Dis. 1959;129:29-40.

25. Narendran R, Frankle WG, Keefe R, Gil R, Martinez D, Slifstein M. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry. Dec 2005;162(12):2352-9. [Medline].

26. Penschuck S, Flagstad P, Didriksen M, Leist M, Michael-Titus AT. Decrease in parvalbum in-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia. Eur J Neurosci. 2005;23(1):279-284.

27. Petersen RC, Stillman RC. Phencyclidine: an overview. NIDA Res Monogr. Aug 1978;(21):1-17. [Medline].

28. Phillips WA, Silverstein SM. Convergence of biological and psychological perspectives on cognitive coordination in schizophrenia. Behav Brain Sci. Feb 2003;26(1):65-82; discussion 82-137. [Medline].

29. Pichot JT, Schmetzer AD. Phencyclidine Bibliography. AAAP - Resource Site for the PGY-5 Curriculum Project - Bibliography. Available at http://www.aaap.org/pgy5/10.10.01pencyclidine.html. Accessed 02/21/2009.

30. Self D. Drug dependence and addiction: neural substrates. Am J Psychiatry. Feb 2004;161(2):223. [Medline].

31. Sena SF, Kazimi S, Wu AH. False-positive phencyclidine immunoassay results caused by venlafaxine and O-desmethylvenlafaxine. Clin Chem. 2002;48(4):676-7. [Medline].

32. Shi WX, Zhang XX. Dendritic glutamate-induced bursting in the prefrontal cortex: further characterization and effects of phencyclidine. J Pharmacol Exp Therapeutics. 2003;305(2):680-687.

33. Shulgin AT, Mac Lean DE. Illicit synthesis of phencyclidine (PCP) and several of its analogs. Clin Toxicol. 1976;9(4):553-60. [Medline].

34. Stefani MR, Moghaddam B. Systemic and prefrontal cortical NMDA receptor blockade differentially affect discrimination learning and set-shift ability in rats. Behav Neurosci. Apr 2005;119(2):420-8. [Medline].

35. Stockard JJ, Werner SS, Aalbers JA, Chiappa KH. Electroencephalographic findings in phencyclidine intoxication. Arch Neurol. Mar 1976;33(3):200-3. [Medline].

36. Weiss CJ, Millman RB. Hallucinogens, phencyclidine, marijuana, inhalants. In: Clinical Textbook of Addictive Disorders. New York, NY: Guilford Press; 1991.

37. West WB, Lou A, Perchersky K, Chadich ME, Appel JB. Antagonism of a PCP drug discrimination by hallucinogens and related drugs. Neuropsychopharmacology. 2000;22(6):618-625. [Full Text].

38. Wong LK, Biemann K. Metabolites of phencyclidine in humans. Biological Mass Spectrometry. April 2005;2(4):204-205.

39. Yago KB, Pitts FN Jr, Burgoyne RW. The urban epidemic of phencyclidine (PCP) use: clinical and laboratory evidence from a public psychiatric hospital emergency service. J Clin Psychiatry. May 1981;42(5):193-6. [Medline].

40. Ziedonis D, Wyatt S. Psychotic disorders. In: Principles of Addiction Medicine. 2^nd ed. Chevy Chase, Md: American Society of Addiction Medicine; 1998.

41. Zukin SR, Zukin RS. Phencyclidine. In: Substance Abuse: A Comprehensive Textbook. Baltimore, Md: Williams & Wilkins; 1992.

Further Reading

Gorelick DA, Balster RL. Phencyclidine (PCP). Back to Psychopharmacology - The Fourth Generation of Progress

Pinchot JT, Schmetzer AD. Phencyclidine bibliography, for AAAP - Resource Site for the PGY-5 Curriculum Project, July 2001

Books and book chapters on PCP:

Hafen B, Frandsen K. Phencyclidine - Angel Dust: By any name not fit for human consumption. Hazelden Foundation, 1980.

Carroll M. The dangerous angel. In: Snyder SH, ed. The Encyclopedia of Psychoactive Drugs. Chelsea House Publishers, 1985, ISBN: 087754753X

Ogelsby EW, Faber S, Faber S. Angel Dust - What everyone should know about PCP. Charing Cross Publishing Company, 1982, ISBN: 0890740666

Keywords

phencyclidine-related psychiatric disorders, PCP, angel dust, crystal, hog, krystal joint, KJ, mintweed, rocket fuel, delta-9-tetrahydrocannabinol, THC, N -methyl-D-aspartate, NMDA, lysergic acid diethylamide, LSD, substance-induced psychosis, 1-(phenylcyclidine) piperidine

Contributor Information and Disclosures

Author

Alan D Schmetzer, MD, Professor, Vice-Chair for Education, and Director of Residency Training in General and Addiction Psychiatry, Department of Psychiatry, Indiana University School of Medicine
Alan D Schmetzer, MD is a member of the following medical societies: American Academy of Addiction Psychiatry, American Academy of Clinical Psychiatrists, American Academy of Psychiatry and the Law, American College of Physician Executives, American Medical Association, American Neuropsychiatric Association, American Psychiatric Association, and Association for Convulsive Therapy
Disclosure: Nothing to disclose.

Coauthor(s)

Roland McGrath, MD, Chairman, Professor, Department of Emergency Medicine, Indiana University School of Medicine
Roland McGrath, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

David R Diaz, MD, Assistant Professor of Clinical Psychiatry, Indiana University School of Medicine; Attending Psychiatrist, Adult Service, Larue D Carter Memorial Hospital; Medical Staff Member, Clarian Health Partners
David R Diaz, MD is a member of the following medical societies: American Psychiatric Association, Indiana Psychiatric Society, and Indiana State Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Barry I Liskow, MD, Professor of Psychiatry, Vice Chairman, Psychiatry Department, Director, Psychiatric Residency Program, University of Kansas School of Medicine; Director, Psychiatric Outpatient Clinic, The University of Kansas Medical Center
Barry I Liskow, MD is a member of the following medical societies: American Academy of Clinical Psychiatrists, American Academy of Psychiatrists in Alcoholism and Addictions, American Medical Association, American Psychiatric Association, and Research Society on Alcoholism
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Iqbal Ahmed, MBBS, Professor, Department of Psychiatry, John A Burns School of Medicine, University of Hawaii
Iqbal Ahmed, MBBS is a member of the following medical societies: Academy of Psychosomatic Medicine, American Association for Geriatric Psychiatry, American Neuropsychiatric Association, and American Psychiatric Association
Disclosure: Nothing to disclose.

CME Editor

Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin
Harold H Harsch, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: lilly Honoraria Speaking and teaching; Forest Labs Honoraria Speaking and teaching; AstraZeneca Honoraria Speaking and teaching; Pfizer Grant/research funds Speaking and teaching; Northstar Grant/research funds Research; Novartis Grant/research funds research; Pfizer  Speaking and teaching; Sanofi-avetis Grant/research funds research; Otsuke Grant/research funds reseach; GlaxoSmithKline Grant/research funds research

Chief Editor

Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA
Stephen Soreff, MD is a member of the following medical societies: American College of Mental Health Administration and American Psychosomatic Society
Disclosure: Nothing to disclose.